NWAM LLC’s Standard BioTools LAB Stock Holding History

NWAM LLC’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-11,358	Closed	-$22.1K	–	562
2023 Q1	$22.1K	Buy	+11,358	New	+$22.4K	﹤0.01%	477

Other funds holding LAB

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

ICM

Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

NIM

Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NWAM LLC's LAB Position: Q2 2023 in Review

NWAM LLC sold out of Standard BioTools (LAB) in Q2 2023, closing a stake of 11,358 shares — an estimated $22.1K sold.

NWAM LLC first reported a position in LAB in Q1 2023 and held it in 1 quarter. The position peaked at $22.1K in Q1 2023. 66 funds tracked by Wall St. Rank hold LAB as of Q2 2023.

NWAM LLC reported no remaining Standard BioTools position as of Q2 2023 after selling out during the quarter.
NWAM LLC sold 11,358 Standard BioTools shares in Q2 2023, an estimated $22.1K.
NWAM LLC first reported a position in Standard BioTools in Q1 2023 and held it in 1 quarter.
NWAM LLC's Standard BioTools position peaked at $22.1K in Q1 2023.
66 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2023.

Based on NWAM LLC's 13F filing for Q2 2023, filed 10 Aug 2023.